Anticancer potential of Trigonella foenum graecum: Cellular and molecular targets

Biomedicine and Pharmacotherapy

Volumn 90, Issue , 2017, Pages 479-491

  El Bairi, Khalid ^a   Ouzir, Mounir ^b   Agnieszka, Najda ^c   Khalki, Loubna ^d  

^a FACULTÉ DES SCIENCES   (Morocco)

^b FACULTÉ DES SCIENCES   (Morocco)

^c UNIVERSITY OF LIFE SCIENCES IN LUBLIN   (Poland)

^d MOHAMMED VI UNIVERSITY OF HEALTH SCIENCES   (Morocco)

Author keywords

anticancer; cancer hallmarks; drug discovery; Fenugreek

Indexed keywords

FENUGREEK EXTRACT; ANTINEOPLASTIC AGENT; FENUGREEK SEED MEAL; PLANT EXTRACT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL INVASION; CELL PROLIFERATION; CHEMICAL COMPOSITION; DRUG DEVELOPMENT; DRUG EFFECT; FENUGREEK; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; ANIMAL; CHEMISTRY; DRUG EFFECTS; PHYTOTHERAPY; PROCEDURES; TRIGONELLA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; OXIDATIVE STRESS; PHYTOTHERAPY; PLANT EXTRACTS; TRIGONELLA;

EID: 85017165364     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2017.03.071     Document Type: Review

References (144)

1. [1] Massagué, J., Obenauf, A.C., Metastatic colonization by circulating tumour cells. Nature 529:529 (2016), 298–306, 10.1038/nature17038.
2. [2] Chaffer, C.L., Weinberg, R.A., How does multistep tumorigenesis really proceed?. Cancer Discov. 5 (2015), 22–24, 10.1158/2159-8290.CD-14-0788.
3. [3] Iwatsuki, M., Mimori, K., Yokobori, T., Ishi, H., Beppu, T., Nakamori, S., Baba, H., Mori, M., Epithelial–mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 101 (2010), 293–299, 10.1111/j. 1349–7006.2009.01419.x.
4. [4] Almendro, V., Marusyk, A., Polyak, K., Cellular heterogeneity and molecular evolution in cancer. Annu. Rev. Pathol. 8 (2013), 277–302, 10.1146/annurev-pathol-020712-163923.
5. [5] Hanahan, D., Weinberg, R.A., The hallmarks of cancer. Cell 100 (2000), 57–70, 10.1016/S0092-8674(00)81683-9.
6. [6] Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674, 10.1016/j.cell.2011.02.013.
7. [7] Floor, S.L., Dumont, J.E., Maenhaut, C., Raspe, E., Hallmarks of cancer: of all cancer cells, all the time?. Trends Mol. Med. 18 (2012), 509–515, 10.1016/j.molmed.2012.06.005.
8. [8] Pietras, K., Östman, A., Hallmarks of cancer: interactions with the tumor stroma. Exp. Cell Res. 316 (2010), 1324–1331, 10.1016/j.yexcr.2010.02.045.
9. [9] Steeg, P.S., Targeting metastasis. Nat. Rev. Cancer 16 (2016), 201–218, 10.1038/nrc.2016.25.
10. [10] Wang, Z., Dabrosin, C., Yin, X., Fuster, M.M., Arreola, A., Rathmell, W.K., Generali, D., Nagaraju, G.P., El-Rayes, B., Ribatti, D., Chen, Y.C., Honoki, K., Fujii, H., Georgakilas, A.G., Nowsheen, S., Amedei, A., Niccolai, E., Amin, A., Ashraf, S.S., Helferich, B., Yang, X., Guha, G., Bhakta, D., Ciriolo, M.R., Aquilano, K., Chen, S., Halicka, D., Mohammed, S.I., Azmi, A.S., Bilsland, A., Keith, W.N., Jensen, L.D., Broad targeting of angiogenesis for cancer prevention and therapy. Semin. Cancer Biol. 35:Suppl (2015), S224–S243, 10.1016/j.semcancer.2015.01.001.
11. [11] Hanahan, D., Rethinking the war on cancer. Lancet 383 (2014), 558–563, 10.1016/S0140-6736(13)62226-6.
12. [12] Mishra, K.P., Ganju, L., Sairam, M., Banerjee, P.K., Sawhney, R.C., A review of high throughput technology for the screening of natural products. Biomed. Pharmacother. 62 (2008), 94–98, 10.1016/j.biopha.2007.06.012.
13. [13] Cragg, G.M., Grothaus, P.G., Newman, D.J., Impact of natural products on developing new anti-cancer agents. Chem. Rev., 109, 2009, 3012, 10.1021/cr900019j.
14. [14] Harvey, A.L., Edrada-Ebel, R., Quinn, R.J., The re-emergence of natural products for drug discovery in the genomics era. Nat. Rev. Drug. Discov. 14 (2015), 111–129, 10.1038/nrd4510.
15. [15] Sung, B., Prasad, S., Yadav, V.R., Aggarwal, B.B., Cancer cell signaling pathways targeted by spice-derived nutraceuticals. Nutr. Cancer 64 (2012), 173–197, 10.1080/01635581.2012.630551.
16. [16] Kinghorn, A.D., Pharmacognosy in the 21 st century. J. Pharm. Pharmacol. 53 (2001), 135–148, 10.1211/0022357011775334.
17. [17] Ganai, S.A., Plant-derived flavone Apigenin: the small-molecule with promising activity against therapeutically resistant prostate cancer. Biomed. Pharmacother. 85 (2016), 47–56, 10.1016/j.biopha.2016.11.130.
18. [18] Sun, Z.L., Dong, J.L., Wu, J., Juglanin induces apoptosis and autophagy in human breast cancer progression via ROS/JNK promotion. Biomed. Pharmacother., 2016, 10.1016/j.biopha.2016.11.030.
19. [19] Teplinsky, E., Herzog, T.J., The efficacy of trabectedin in treating ovarian cancer. Expert Opin. Pharmacother. 18 (2017), 313–323, 10.1080/14656566.2017.1285282.
20. [20] Shabbeer, S., Sobolewski, M., Anchoori, R.K., Kachhap, S., Hidalgo, M., Jimeno, A., Davidson, N., Carducci, M.A., Khan, S.R., Fenugreek: a naturally occurring edible spice as an anticancer agent. Cancer. Biol. Ther. 8 (2009), 272–278, 10.4161/cbt.8.3.7443.
21. [21] Aggarwal, B.B., Kunnumakkara, A.B., Harikumar, K.B., Tharakan, S.T., Sung, B., Anand, P., Potential of spice-derived phytochemicals for cancer prevention. Planta. Med. 74 (2008), 1560–1569, 10.1055/s-2008-1074578.
22. [22] Kenny, O., Smyth, T.J., Hewage, C.M., Brunton, N.P., Antioxidant properties and quantitative UPLC-MS analysis of phenolic compounds from extracts of fenugreek (Trigonella foenum-graecum) seeds and bitter melon (Momordica charantia) fruit. Food Chem. 141 (2013), 4295–4302, 10.1016/j.foodchem.2013.07.016.
23. [23] Bahmani, M., Shirzad, H., Mirhosseini, M., Mesripour, A., Rafieian-Kopaei, M., A review on ethnobotanical and therapeutic uses of fenugreek (Trigonella foenum-graceum L). J. Evid. Based Complement. Altern. Med. 21 (2016), 53–62, 10.1177/2156587215583405.
24. [24] Hua, S., Li, Y., Su, L., Liu, X., Diosgenin ameliorates gestational diabetes through inhibition of sterol regulatory element-binding protein-1. Biomed. Pharmacother., 2016, 10.1016/j.biopha.2016.10.049.
25. [25] Hirakawa, N., Okauchi, R., Miura, Y., Yagasaki, K., Anti-invasive activity of niacin and trigonelline against cancer cells. Biotech. Biochem. 69 (2005), 653–658, 10.1271/bbb.69.653.
26. [26] Allred, K.F., Yackley, K.M., Vanamala, J., Allred, C.D., Trigonelline is a novel phytoestrogen in coffee beans. J. Nutr. 139 (2009), 833–838.
27. [27] Ravishankar, D., Rajora, A.K., Greco, F., Osborn, H.M., Flavonoids as prospective compounds for anti-cancer therapy. Int. J. Biochem. Cell Biol. 45 (2013), 2821–2831, 10.1016/j.biocel.2013.10.004.
28. [28] Leyva-López, N., Gutierrez-Grijalva, E.P., Ambriz-Perez, D.L., Heredia, J.B., Flavonoids as cytokine modulators: a possible therapy for inflammation-related diseases. Int. J. Mol. Sci., 17, 2016, 10.3390/ijms17060921E921.
29. [29] Garg, Ramesh C., Fenugreek multiple health benefits. Gupta, Ramesh C., (eds.) Nutraceuticals: Efficacy, Safety and Toxicity, 2016, Academic Press, 599–617, 10.1016/B978-0-12-802147-7.00044-9.
30. [30] Ahmad, A., Alghamdi, S.S., Mahmood, K., Afzal, M., Fenugreek a multipurpose crop: potentialities and improvements. Saudi J. Biol. Sci. 23 (2016), 300–310, 10.1016/j.sjbs.2015.09.015.
31. [31] Raju, J., Rao, ChV., Diosgenin, a Steroid Saponin Constituent of Yams and Fenugreek: Emerging Evidence for Applications, Bioactive Compounds Medicine in Phytomedicine. Rasooli, Iraj, (eds.), 2012, InTech. 978-953-307-805-2.
32. [32] Al-Daghri, N.M., Alokail, M.S., Alkharfy, K.M., Mohammed, A.K., Abd-Alrahman, S.H., Yakout, S.M., Amer, O.E., Krishnaswamy, S., Fenugreek extract as an inducer of cellular death via autophagy in human T lymphoma Jurkat cells. BMC Complement. Altern. Med., 12, 2012, 202, 10.1186/1472-6882-12-202.
33. [33] Khalil, M.I.M., Ibrahim, M.M., El-Gaaly, G.A., Sultan, A.S., Trigonella foenum (fenugreek) induced apoptosis in hepatocellular carcinoma cell line, HepG2, mediated by upregulation of p53 and proliferating cell nuclear antigen. Biol. Med. Res. Int., 2015, 10.1155/2015/914645.
34. [34] Yadav, U.C., Baquer, N.Z., Pharmacological effects of Trigonella foenum-graecum L. in health and disease. Pharm. Biol. 52 (2014), 243–254, 10.3109/13880209.2013.826247.
35. [35] Sies, H., Oxidative stress: a concept in redox biology and medicine. Redox Biol. 4 (2015), 180–183, 10.1016/j.redox.2015.01.002.
36. [36] Reuter, S., Gupta, S.C., Chaturvedi, M.M., Aggarwal, B.B., Oxidative stress, inflammation, and cancer: how are they linked?. Free Radic. Biol. Med. 49 (2010), 1603–1616, 10.1016/j.freeradbiomed.2010.09.006.
37. [37] Sosa, V., Moliné, T., Somoza, R., Paciucci, R., Kondoh, H., LLeonart, M.E., Oxidative stress and cancer: an overview. Ageing Res. Rev. 12 (2013), 376–390, 10.1016/j.arr.2012.10.004.
38. [38] Ogura, S., Shimosawa, T., Oxidative stress and organ damages. Curr. Hypertens. Rep., 16, 2014, 452, 10.1007/s11906-014-0452-x.
39. [39] Bhat, A.H., Dar, K.B., Anees, S., Zargar, M.A., Masood, A., Sofi, M.A., Ganie, S.A., Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight. Biomed. Pharmacother. 74 (2015), 101–110, 10.1016/j.biopha.2015.07.025.
40. [40] Klaunig, J.E., Wang, Z., Pu, X., Zhou, S., Oxidative stress and oxidative damage in chemical carcinogenesis. Toxicol. Appl. Pharmacol. 254 (2011), 86–99, 10.1016/j.taap.2009.11.028.
41. [41] Kang, S.W., Lee, S., Lee, E.K., ROS and energy metabolism in cancer cells: alliance for fast growth. Arch. Pharm. Res. 38 (2015), 338–345, 10.1007/s12272-015-0550-6.
42. [42] Landry, W.D., Cotter, T.G., ROS signalling, NADPH oxidases and cancer. Biochem. Soc. Trans. 42 (2014), 934–948, 10.1042/BST20140060.
43. [43] Sabharwal, S.S., Schumacker, P.T., Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles’ heel?. Nat. Rev. Cancer 14 (2014), 709–721, 10.1038/nrc3803.
44. [44] Pages, F., Galon, J., Dieu-Nosjean, M.C., Tartour, E., Sautes-Fridman, C., Fridman, W.H., Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29 (2010), 1093–1102, 10.1038/onc.2009.416.
45. [45] Coussens, L.M., Zitvogel, L., Palucka, A.K., Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science 339 (2013), 286–291, 10.1126/science.1232227.
46. [46] Forester, S.C., Lambert, J.D., The role of antioxidant versus pro-oxidant effects of green tea polyphenols in cancer prevention. Mol. Nutr. Food Res. 55 (2011), 844–854, 10.1002/mnfr.201000641.
47. [47] Milkovic, L., Siems, W., Siems, R., Zarkovic, N., Oxidative stress and antioxidants in carcinogenesis and integrative therapy of cancer. Curr. Pharm. Des. 20 (2014), 6529–6542, 10.2174/1381612820666140826152822.
48. [48] Bonner, M.Y., Arbiser, J.L., The antioxidant paradox: what are antioxidants and how should they be used in a therapeutic context for cancer. Fut. Med. Chem. 6 (2014), 1413–1422, 10.4155/fmc.14.86.
49. [49] Goodma, M., Bostick, R.M., Kucuk, O., Jones, D.P., Clinical trials of antioxidants as cancer prevention agents: past, present, and future. Free Radic. Biol. Med. 51 (2011), 1068–1084, 10.1016/j.freeradbiomed.2011.05.018.
50. [50] Fuchs-Tarlovsky, V., Role of antioxidants in cancer therapy. Nutrition 29 (2013), 15–21, 10.1016/j.nut.2012.02.014.
51. [51] Roleira, F.M., Tavares-da-Silva, E.J., Varela, C.L., Costa, S.C., Silva, T., Garrido, J., Borges, F., Plant derived and dietary phenolic antioxidants: anticancer properties. Food Chem. 15 (2015), 235–258, 10.1016/j.foodchem.2015.03.039.
52. [52] Dai, J., Mumper, R.J., Plant phenolics: extraction, analysis and their antioxidant and anticancer properties. Molecules 15 (2010), 7313–7352, 10.3390/molecules15107313.
53. [53] Mahbub, A.A., Le Maitre, C.L., Haywood-Small, S.L., Cross, N.A., Jordan-Mahy, N., Polyphenols act synergistically with doxorubicin and etoposide in leukaemia cell lines. Cell Death Discov., 1, 2015, 15043, 10.1038/cddiscovery.2015.43.
54. [54] Juárez, P., Plant-derived anticancer agents: a promising treatment for bone metastasis. Bonekey. Rep., 3, 2014, 599, 10.1038/bonekey.2014.94.
55. [55] Dixit, P., Ghaskadbi, S., Mohan, H., Devasagayam, T.P., Antioxidant properties of germinated fenugreek seeds. Phytother. Res. 19 (2005), 977–983, 10.1002/ptr.1769.
56. [56] Gupta, S.K., Kalaiselvan, V., Srivastava, S., Saxena, R., Agrawal, S.S., Trigonella foenum-graecum (Fenugreek) protects against selenite-induced oxidative stress in experimental cataractogenesis. Biol. Trace Elem. Res. 136 (2010), 258–268, 10.1007/s12011-009-8540-5.
57. [57] Al-Sultan, S.I., El-Bahr, S.M., Effect of aqueous extract of fenugreek (Trigonella foenum-graecum L.) on selected biochemical and oxidative stress biomarkers in rats intoxicated with carbon tetrachloride. Int. J. Pharmacol. 11 (2015), 43–49, 10.3923/ijp.2015.43.49.
58. [58] Mayakrishnan, T., Nakkala, J.R., Jeepipalli, S.P.K., et al. Fenugreek seed extract and its phytocompounds-trigonelline and diosgenin arbitrate their hepatoprotective effects through attenuation of endoplasmic reticulum stress and oxidative stress in type 2 diabetic rats. Eur. Food. Res. Technol., 240, 2015, 223, 10.1007/s00217-014-2322-9.
59. [59] Reddy, R.R.L., Srinivasan, K., Hepatoprotective and antioxidant effect of fenugreek (Trigonella foenum-graecum) seeds in mice under lithogenic condition. J. Food. Biochem. 35 (2011), 1619–1626, 10.1111/j.1745-4514.2010.00488.x.
60. [60] Sakr, S.A., Abo-El-Yazid, S.M., Effect of fenugreek seed extract on adriamycin-induced hepatotoxicity and oxidative stress in albino rats. Toxicol. Ind. Health 28 (2012), 876–885, 10.1177/0748233711425076.
61. [61] Abdel-Daim, M.M., Abd Eldaim, M.A., Hassan, A.G., Trigonella foenum-graecum ameliorates acrylamide-induced toxicity in rats: roles of oxidative stress, proinflammatory cytokines, and DNA damage. Biochem. Cell Biol. 93 (2014), 192–198, 10.1139/bcb-2014-0122.
62. [62] Xue, W., Lei, J., Li, X., Zhang, R., Trigonella foenum-graecum seed extract protects kidney function and morphology in diabetic rats via its antioxidant activity. Nutr. Res. 31 (2011), 555–562, 10.1016/j.nutres.2011.05.010.
63. [63] Sindhu, G., Ratheesh, M., Shyni, G.L., Nambisan, B., Helen, A., Anti-inflammatory and antioxidative effects of mucilage of Trigonella foenum graecum (Fenugreek) on adjuvant induced arthritic rats. Int. Immunopharmacol. 12 (2012), 205–211.
64. [64] Morani, A.S., Bodhankar, S.L., Mohan, V., Thakurdesai, P.A., Ameliorative effects of standardized extract from Trigonella foenum-graecum L. seeds on painful peripheral neuropathy in rats. Asian Pac. J. Trop. Med. 5 (2012), 385–390, 10.1016/S1995-7645(12)60064-9.
65. [65] Subhashini, N., Nagarajan, G., Kavimani, S., Anti-inflmmatory and in vitro antioxidant property of Trigonella foenum graecum seeds. J. Pharmacol. Toxicol. 6 (2011), 371–380, 10.3923/jpt.2011.371.380.
66. [66] Mandegary, A., Pournamdari, M., Sharififar, F., Pournourmohammadi, S., Fardiar, R., Shooli, S., Alkaloid and flavonoid rich fractions of fenugreek seeds (Trigonella foenum-graecum L.) with antinociceptive and anti-inflammatory effects. Food Chem. Toxicol. 50 (2012), 2503–2507, 10.1016/j.fct.2012.04.020.
67. [67] Kawabata, T., Cui, M.Y., Hasegawa, T., Takano, F., Ohta, T., Anti-inflammatory and antimelanogenic steroidal saponin glycosides from fenugreek (Trigonella foenum graecum L.) seeds. Planta Med. 77 (2011), 705–710, 10.1055/s-0030-1250477.
68. [68] Liu, Y., Kakani, R., Muraleedharan, G.N., Compounds in functional food fenugreek spice exhibit anti-inflammatory and antioxidant activities. Food Chem. 131 (2012), 1187–1192, 10.1016/j.foodchem.2011.09.102.
69. [69] Hao-Peng, Y.A.N.G., Lei, Y.U.E., JIANG, W.W., Qian, L.I.U., Jun-Ping, K.O.U., Bo-Yang, Y.U., Diosgenin inhibits tumor necrosis factor-induced tissue factor activity and expression in THP-1 cells via down-regulation of the NF-(B, Akt, and MAPK signaling pathways. Chin. J. Nat. Med. 11 (2013), 608–615, 10.1016/S1875-5364(13)60070-9.
70. [70] Zailei, R., Ali, S., Khorshid, F., Albar, H., Karrouf, G., Ameliorative effect of Trigonella foenum graecum (fenugreek) seeds infusion on mouse lymphocytic leukemia cells induced ascities in mice. Glob. J. Pharmacol. 10 (2016), 74–81, 10.5829/idosi.gjp.2016.10.03.105109F.
71. [71] Bentrad, V., Zaletok, S., Zelena, O., Antitumor activity of fenugreek (Trigonella foenum graecum L.) powder seeds in vivo. Ann. Oncol. 26:Supplement 7 (2015), 106–151, 10.1093/annonc/mdv472.78.
72. [72] Alsemari, A., Alkhodairy, F., Aldakan, A., Al-Mohanna, M., Bahoush, E., Shinwari, Z., Alaiya, A., The selective cytotoxic anti-cancer properties and proteomic analysis of Trigonella Foenum-Graecum. BMC Complement. Altern. Med., 14, 2014, 114, 10.1186/1472-6882-14-114.
73. [73] Alshatwi, A.A., Shafi, G., Hasan, Y.N., Syed, N.A., Khoja, K.K., Fenugreek induced apoptosis in breast cancer MCF-7 cells mediated independently by fas receptor change. Asian Pac. J. Cancer. Prev. 14 (2013), 5783–5788, 10.7314/APJCP.2013.14.10.5783.
74. [74] Chatterjee, S., Kumar, M., Kumar, A., Chemomodulatory effect of Trigonella foenum graecum (L.) seed extract on two stage mouse skin carcinogenesis. Toxicol. Int. 19 (2012), 287–294, 10.4103/0971-6580.103670.
75. [75] Khoja, K.K., Shaf, G., Hasan, T.N., Syed, N.A., Al-Khalifa, A.S., Al-Assaf, A.H., Alshatwi, A.A., Fenugreek, a naturally occurring edible spice, kills MCF-7 human breast cancer cells via an apoptotic pathway. Asian Pac. J. Cancer Prev. 12 (2011), 3299–3304.
76. [76] Prabhu, A., Krishnamoorthy, M., Anticancer activity of Trigonella foenum-graecum on Ehrlich Ascites carcinoma in Mus musculus system. J. Pharm. Res. 3 (2010), 1181–1183.
77. [77] Ardelean, A., Pribac, G., Hermenean, A., et al. Cytostatic and cytotoxic effects of Trigonella foenum graecum (fenugreek) seed extract. Stud. Univ. Vasile Goldiş Seria Ştiinţele Vieţii 20 (2010), 25–29.
78. [78] Shishodia, S., Aggarwal, B.B., Diosgenin inhibits osteoclastogenesis, invasion, and proliferation through the downregulation of Akt, I kappa B kinase activation and NF-kappa B-regulated gene expression. Oncogene 25 (2006), 1463–1473, 10.1038/sj.onc.1209194.
79. [79] Devasena, T., Menon, P.V., Fenugreek seeds modulate 1,2-dimethylhydrazine-induced hepatic oxidative stress during colon carcinogenesis. Ital. J. Biochem. 56 (2007), 28–34.
80. [80] Amin, A., Alkaabi, A., Al-Falasi, S., Daoud, S.A., Chemopreventive activities of Trigonella foenum-graecum (fenugreek) against breast cancer. Cell Biol. Int. 29 (2005), 687–694, 10.1016/j.cellbi.2005.04.004.
81. [81] Alkofahi, A., Batshoun, R., Owais, W., Najib, N., Biological activity of some Jordanian medicinal plant extracts. Fitoterapia 67 (1996), 435–442.
82. [82] Sultan, A.S., Fayala, A.S., Elkamel, M., Bakir, R., Foad, F., Trigonella foenum (fenugreek) inhibited cancer stem cell properties and increased sensitivity to Doxorubicin resistant ZR-75-1 human breast cancer cell line by targeting mutant p53 and Notch-4. Cancer Res., 2016, 318.
83. [83] Sur, P., Das, M., Gomes, A., Vedasiromoni, J.R., Sahu, N.P., Banerjee, S., Sharma, R.M., Ganguly, D.K., Vedasiromoni, J.R., Sahu, N.P., Banerjee, S., Sharm, R.M., Ganguly, D.K., Trigonella foenum-graecum (fenugreek) seed extract as an antineoplastic agent. Phytother. Res. 15 (2001), 257–259, 10.1002/ptr.718.
84. [84] Al-Oqail, M.M., Farshori, N.N., Al-Sheddi, E.S., Musarrat, J., Al-Khedhairy, A.A., Siddiqui, M.A., In vitro cytotoxic activity of seed oil of fenugreek against various cancer cell lines. Asian Pac. J. Cancer. Prev. 14 (2013), 1829–1832, 10.7314/apjcp.2013.14.3.1829.
85. [85] Moalic, S., Liagre, B., Corbiere, C., Bianchi, A., Dauca, M., et al. A plant steroid, diosgenin, induces apoptosis, cell cycle arrest and COX activity in osteosarcoma cells. FEBS Lett 506 (2001), 225–230, 10.1016/S0014-5793(01)02924-6.
86. [86] Corbiere, C., Liagre, B., Bianchi, A., Bordji, K., Dauca, M., Netter, P., Beneytout, J.L., Different contribution of apoptosis to the antiproliferative effects of diosgenin and other plant steroids, hecogenin and tigogenin, onhuman 1547 osteosarcoma cells. Int. J. Oncol. 22 (2003), 899–905, 10.3892/ijo.22.4.899.
87. [87] Leger, D.Y., Liagre, B., Cardot, P.J., Beneytout, J.L., Battu, S., Diosgenin dose-dependent apoptosis and differentiation induction in human erythroleukemia cell line and sedimentation field-flow fractionation monitoring. Anal. Biochem. 335 (2004), 267–278, 10.1016/j.ab.2004.09.008.
88. [88] Malisetty, V.S., Patlolla, J.M.R., Raju, J., Marcus, L.A., Choi, C.L., Rao, C.V., Chemoprevention of colon cancer by diosgenin, a steroidal saponin constituent of fenugreek. Proc. Am. Assoc. Cancer Res., 46, 2005, 2473.
89. [89] Wang, S.L., Cai, B., Cui, C.B., Liu, H.W., Wu, C.F., Yao, X.S., Diosgenin-3-O-(-L-rhamnopyranosyl-(1→4)-β-D-glucopyranoside obtained as a new anticancer agent from Dioscorea futschauensis induces apoptosis on human colon carcinoma HCT-15 cells via mitochondria-controlled apoptotic pathway. J. Asian Nat. Prod. Res. 6 (2004), 115–125, 10.1080/1028602031000147357.
90. [90] Srinivasan, S., Koduru, S., Kumar, R., Venguswamy, G., Kyprianou, N., Damodaran, C., Diosgenin targets Akt-mediated prosurvival signaling in human breast cancer cells. Int. J. Cancer. 125 (2009), 961–967, 10.1002/ijc.24419.
91. [91] Yan, L.L., Zhang, Y.J., Gao, W.Y., Man, S.L., Wang, Y., In vitro and in vivo anticancer activity of steroid saponins of Paris polyphylla var. yunnanensis. Exp. Oncol. 31 (2009), 27–32.
92. [92] Chen, P.S., Shih, Y.W., Huang, H.C., Cheng, H.W., Diosgenin, a steroidal saponin, inhibits migration and invasion of human prostate cancer PC-3 cells by reducing matrix metalloproteinases expression. PLoS One, 6, 2011, e20164, 10.1371/journal.pone.0020164.
93. [93] Das, S., Dey, K.K., Dey, G., Pal, I., Majumder, A., Maiti Choudhury, S., Kundu, S.C., Mandal, M., Antineoplastic and apoptotic potential of traditional medicines thymoquinone and diosgenin in squamous cell carcinoma. PLoS One, 7, 2012, e46641, 10.1371/journal.pone.0046641.
94. [94] Miyoshi, N., Nagasawa, T., Mabuchi, R., Yasui, Y., Wakabayashi, K., Tanaka, T., Ohshima, H., Chemoprevention of azoxymethane/dextran sodium sulfate-induced mouse colon carcinogenesis by freeze-dried yam sanyaku and its constituent diosgenin. Cancer Prev. Res. 4 (2011), 924–934, 10.1158/1940-6207.CAPR-10-0279.
95. [95] Corbiere, C., Liagre, B., Terro, F., Beneytout, J.L., Induction of antiproliferative effect by diosgenin through activation of p53, release of apoptosis inducing factor (AIF) and modulation of caspase-3 activity in different human cancer cells. Cell. Res. 14 (2004), 188–196, 10.1038/sj.cr.7290219.
96. [96] Sowmyalakshmi, S., Ranga, R., Gairola, C.G., Chendil, D., Effect of diosgenin (fenugreek) on breast cancer cells. Proc. Am. Assoc. Cancer Res., 46, 2005, 1382.
97. [97] Li, F., Fernandez, P.P., Rajendran, P., Hui, K.M., Sethi, G., Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells. Cancer Lett. 292 (2010), 197–207, 10.1016/j.canlet.2009.12.003.
98. [98] Liu, M.J., Wang, Z., Ju, Y., Wong, R.N., Wu, Q.Y., Diosgenin induces cell cycle arrest and apoptosis in human leukemia K562 cells with the disruption of Ca2+ homeostasis. Cancer Chemoth Pharmacol. 55 (2005), 79–90, 10.1007/s00280-004-0849-3.
99. [99] Raju, J., Patlolla, J.M., Swamy, M.V., Rao, C.V., Diosgenin, a steroid saponin of Trigonella foenum-graecum (Fenugreek), inhibits azoxymethane-induced aberrant crypt foci formation in F344 rats and induces apoptosis in HT-29 human colon cancer cells. Cancer Epidemiol. Biomark. Prev. 13 (2004), 1392–1398.
100. [100] Chiang, C.T., Way, T.D., Tsai, S.J., Lin, J.K., Diosgenin, a naturally occurring steroid, suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt, mTOR and JNK phosphorylation. FEBS Lett. 581 (2007), 5735–5742, 10.1016/j.febslet.2007.11.021.
101. [101] Liao, J.C., Lee, K.T., You, B.J., Lee, C.L., Chang, W.T., Wu, Y.C., Lee, H.Z., Raf/ERK/Nrf2 signaling pathway and MMP-7 expression involvement in the trigonelline-mediated inhibition of hepatocarcinoma cell migration. Food Nutr. Res., 59, 2015, 29884, 10.3402/fnr.v59.29884.
102. [102] Babaei, M., Haeri, M.R., Mousavi, S.Z., Khazen, M., Cytotoxic Effect of 4-hydroxyisoleucine on liver cancer cell line. Qom. Univ. Med. Sci. J. 9 (2015), 1–6.
103. [103] E. Zeiger, R. Tice, Trigonelline [535–83–1] Review of Toxicological Literature. Integrated Laboratory Systems, (1997) Available online: http://ntp.niehs.nih.gov/ntp/htdocs/chem_background/exsumpdf/trigonelline_508.pdf.
104. [104] Yum, C.H., Hyun, J.Y., Geun, E.J., Cytotoxicity of dioscin and biotransformed fenugreek. J. Korean Soc. Appl. Biol. Chem. 53 (2010), 470–477, 10.3839/jksabc.2010.072.
105. [105] Hibasami, H., Moteki, H., Ishikawa, H., Imai, K., Yoshioka, K., Ishii, Y., Komiya, T., Protodioscin isolated from fenugreek (Trigonella foenumgraecum) induces cell death and morphological change indicative of apoptosis in leukemic cell line H-60 but not in gastric cancer cell line KATO III. Int. J. Mol. Med. 11 (2003), 23–26.
106. [106] Mohammad, Y., Fazili, K.M., Bhat, K.A., Ara, T., Synthesis and biological evaluation of novel 3-O-tethered triazoles of diosgenin as potent antiproliferative agents. Steroids 118 (2017), 1–8, 10.1016/j.steroids.2016.11.003.
107. [107] Lepage, C., Léger, D.Y., Bertrand, J., Martin, F., Beneytout, J.L., Liagre, B., Diosgenin induces death receptor-5 through activation of p38 pathway and promotes TRAIL-induced apoptosis in colon cancer cells. Cancer Lett. 301 (2011), 193–202, 10.1016/j.canlet.2010.12.00.
108. [108] Romero-Hernandez, L.L., Merino-Montiel, P., Montiel-Smith, S., Meza-Reyes, S., Vega-Báez, J.L., Abasolo, I., Schwartz, S. Jr., López, O., Fernández-Bolaños, J.G., Diosgenin-based thio (seleno) ureas and triazolyl glycoconjugates as hybrid drugs. Antioxidant and antiproliferative profile. Eur. J. Med. Chem. 99 (2015), 67–81, 10.1016/j.ejmech.2015.05.018.
109. [109] Cai, B., Liao, A., Lee, K.K., Ban, J.S., Yang, H.S., Im, Y.J., Chun, C., Design, synthesis of methotrexate-diosgenin conjugates and biological evaluation of their effect on methotrexate transport-resistant cells. Steroids 116 (2016), 45–51, 10.1016/j.steroids.2016.10.006.
110. [110] Jiang, S., Fan, J., Wang, Q., Ju, D., Feng, M., Li, J., Guan, Z.B., An, D., X.Wang, L.Ye, Diosgenin induces ROS-dependent autophagy and cytotoxicity via mTOR signaling pathway in chronic myeloid leukemia cells. Phytomedicine 23 (2016), 243–252, 10.1016/j.phymed.2016.01.010.
111. [111] Jagadeesan, J., Langeswaran, K., Gowthamkumar, S., Balasubramanian, M.P., Diosgenin exhibits beneficial efficiency on human mammary carcinoma cell line MCF-7 and against N-nitroso-N-methylurea (NMU) induced experimental mammary carcinoma. Biomed. Prev. Nutr. 3 (2013), 381–388, 10.1016/j.bionut.2013.06.009.
112. [112] Wang, Z., Dabrosin, C., Yin, X., Fuster, M.M., Arreola, A., Rathmell, W.K., Generali, D., Nagaraju, G.P., El-Rayes, B., Ribatti, D., Chen, Y.C., Honoki, K., Fujii, H., Georgakilas, A.G., Nowsheen, S., Amedei, A., Niccolai, E., Amin, A., Ashraf, S.S., Helferich, B., Yang, X., Guha, G., Bhakta, D., Ciriolo, M.R., Aquilano, K., Chen, S., Halicka, D., Mohammed, S.I., Azmi, A.S., Bilsland, A., Keith, W.N., Jensen, L.D., Broad targeting of angiogenesis for cancer prevention and therapy. Semin. Cancer Biol. 35:Suppl (2015), S224–S243, 10.1016/j.semcancer.2015.01.001.
113. [113] Shaw, D., Clamp, A., Jayson, G.C., Angiogenesis as a target for the treatment of ovarian cancer. Curr. Opin. Oncol. 25 (2013), 558–565, 10.1097/CCO.0b013e328363e0da.
114. [114] Gavalas, N.G., Liontos, M., Trachana, S.P., Bagratuni, T., Arapinis, C., Liacos, C., Dimopoulos, M.A., Bamias, A., Angiogenesis-related pathways in the pathogenesis of ovarian cancer. Int. J. Mol. Sci. 14 (2013), 15885–15909, 10.3390/ijms140815885.
115. [115] Bamias, A., Pignata, S., Pujade-Lauraine, E., Angiogenesis: a promising therapeutic target for ovarian cancer. Crit. Rev. Oncol. Hematol. 84 (2012), 314–326, 10.1016/j.critrevonc.2012.04.002.
116. [116] Sun, W., Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy. J. Hematol. Oncol., 11, 2012, 63, 10.1186/1756-8722-5-63.
117. [117] El Bairi, K., EL-Meghawry, E.A., Rahman, H., Guaadaoui, A., Agnieszka, N., Natural products against cancer angiogenesis. Tumor Biol. 37 (2016), 14513–14536, 10.1007/s13277-016-5364-8.
118. [118] Selim, S., Al Jaouni, S., Anti-inflammatory, antioxidant and antiangiogenic activities of diosgenin isolated from traditional medicinal plant, Costus speciosus (Koen ex Retz.) Sm. Nat. Prod. Res. 30 (2016), 1830–1833, 10.1080/14786419.2015.1065493.
119. [119] He, Z., Chen, H., Li, G., Zhu, H., Gao, Y., Zhang, L., Sun, J., Diosgenin inhibits the migration of human breast cancer MDA-MB-231 cells by suppressing Vav2 activity. Phytomedicine 21 (2014), 871–876, 10.1016/j.phymed.2014.02.002.
120. [120] Mao, Z.J., Tang, Q.J., Zhang, C.A., Qin, Z.F., Pang, B., Wei, P.K., Liu, B., Chou, Y.N., Anti-proliferation and anti-invasion effects of diosgenin on gastric cancer BGC-823 cells with HIF-1αshRNAs. Int. J. Mol. Sci. 13 (2012), 6521–6533, 10.3390/ijms13056521.
121. [121] Jagadeesan, J., Langeswaran, K., Gowthamkumar, S., Balasubramanian, M.P., Diosgenin exhibits beneficial efficiency on human mammary carcinoma cell line MCF-7 and against N-nitroso-N-methylurea (NMU) induced experimental mammary carcinoma. Biomed. Prev. Nutr. 3:4 (2013), 381–388, 10.1016/j.bionut.2013.06.009.
122. [122] Campagna, M.C., Chemotherapy complications. Hosp. Med. Clin. 5 (2016), 400–412, 10.1016/j.ehmc.2016.02.001.
123. [123] Sonis, S., Keefe, D.M., Pathobiology of Cancer Regimen-Related Toxicities. 2013, Springer Science + Business Media, New York.
124. [124] Dohle, G.R., Male infertility in cancer patients: review of the literature. Int. J. Urol. 17 (2010), 327–331, 10.1111/j. 1442-2042.2010.02484.x.
125. [125] Florea, A.M., Büsselberg, D., Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers 3 (2011), 1351–1371, 10.3390/cancers3011351.
126. [126] Hamza, A.A., Elwy, H.M., Badawi, A.M., Fenugreek seed extract attenuates cisplatin-induced testicular damage in Wistar rats. Andrologia 48 (2016), 211–221, 10.1111/and.12435.
127. [127] Sakr, S.A., El-Shenawy, S.M., El-shabka, A.M., Aqueous fenugreek seed extract ameliorates adriamycin-induced cytotoxicity and testicular alterations in albino Rats. Reprod. Sci. 19 (2012), 70–80, 10.1177/1933719111413301.
128. [128] Ouzir, M., El Bairi, K., Amzazi, S., Toxicological properties of fenugreek (Trigonella foenum graecum). Food Chem. Toxicol. 96 (2016), 145–154, 10.1016/j.fct.2016.08.003.
129. [129] Khalki, L., BaM'hamed, S., Bennis, M., Chait, A., Sokar, Z., Evaluation of the developmental toxicity of the aqueous extract from Trigonella foenum-graecum (L.) in mice. J. Ethnopharmacol. 131 (2010), 321–325, 10.1016/j.jep.2010.06.033.
130. [130] Khalki, L., Bennis, M., Sokar, Z., Ba-M'hamed, S., The developmental neurobehavioral effects of fenugreek seeds on prenatally exposed mice. J. Ethnopharmacol. 139 (2012), 672–677, 10.1016/j.jep.2011.12.011.
131. [131] Sabzevari, O., Abdollahi, M., Aminian, G.H., Minaee, B., Study of teratogenic effect of fenugreek extract on rat embryos. Rev. de Fitoterapia, 2, 2002, 200.
132. [132] Echadli, A., Retentissement fœtal Et néonatal De La Prise Des médicaments Et/ou Des Plantes médicinales Par La Parturiente, à Propos De 81 Cas. Dissertation. 2006, University Mohamed V.
133. [133] Skalli, S., Malformations associées à la prise de fenugrecaucours de la grossesse. Bulletin d'Informations de Pharmacovigilance. 2006, 3.
134. [134] Khalki, L., Ba M'hamed, S., Sokar, Z., Bennis, M., Vinay, L., et al. Prenatal exposure to fenugreek impairs sensorimotor development and the operation of spinal Cord networks in mice. PLoS One, 8, 2013, e80013, 10.1371/journal.pone.0080013.eCollection.
135. [135] Nicolie, B., Leduc, V., rouet, M., Food cross-allergy between fenugreek seeds (Trigonella foenum-graecum) and peanut. Allergy 62 (2007), 365–366.
136. [136] Moghadam, F.H., Vakili-Zarch, B., Shafiee, M., Mirjalili, A., Fenugreek seed extract treats peripheral neuropathy in pyridoxine induced neuropathic mice. Excli. J. 12 (2013), 282–290.
137. [137] Muraki, E., Hayashi, Y., Chiba, H., Tsunoda, N., Kasono, K., Dose-dependent effects, safety and tolerability of fenugreek in diet-induced metabolic disorders in rats. Lipids Health Dis., 10, 2011, 240, 10.1186/1476-511X-10-240.
138. [138] Basch, E., Ulbricht, C., Kuo, G., Szapary, P., Smith, M., Therapeutic applications of fenugreek. Altern. Med. Rev. 8 (2003), 20–27.
139. [139] Heck, A.M., DeWitt, B.A., Lukes, A.L., Potential interactions between alternative therapies and warfarin. Am. J. Health Syst. Pharm. 57 (2000), 1221–1227 (quiz 1228-30).
140. [140] Lambert, J.P., Cormier, J., Potential interaction between warfarin and boldo-fenugreek. Pharmacotherapy 21 (2001), 509–512, 10.1592/phco.21.5.509.34492.
141. [141] Abebe, W., Herbal medication: potential for adverse interactions with analgesic drugs. J. Clin. Pharm. Ther. 27 (2002), 391–401, 10.1046/j.1365-2710.2002.00444.x.
142. [142] Al-Ghamdi, H., Sabbah, R., Martin, J., Patay, Z., Primary T-cell lymphoma of the brain in children: a case report and literature review. Pediatr. Hematol. Oncol. 17 (2000), 341–343, 10.1080/088800100276343.
143. [143] Nathan, J., Panjwani, S., Mohan, V., Joshi, V., Thakurdesai, P.A., Efficacy and safety of standardized extract of trigonella foenum graecum l seeds as an adjuvant to L-Dopa in the management of patients with Parkinson's disease. Phytother. Res. 28 (2014), 172–178, 10.1002/ptr.4969.
144. [144] Sudheeran, S.P., Jacob, D., Mulakal, J.N., Nair, G.G., Maliakel, A., Maliakel, B., Krishnakumar, I.M., Safety, tolerance, and enhanced efficacy of a bioavailable formulation of curcumin with fenugreek dietary fiber on occupational stress: a randomized, double-Blind, placebo-controlled pilot study. J. Clin. Psychopharmacol. 36:3 (2016), 236–243, 10.1097/JCP.0000000000000508.